The estimated Net Worth of Vaughn Mgadicke Ansbert Kai... is at least $50.2 million dollars as of 11 March 2013. Vaughn Kai owns over 500,000 units of Pacira BioSciences Inc stock worth over $36,276,227 and over the last 14 years Vaughn sold PCRX stock worth over $13,930,000.
Vaughn has made over 2 trades of the Pacira BioSciences Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Vaughn sold 500,000 units of PCRX stock worth $13,930,000 on 11 March 2013.
The largest trade Vaughn's ever made was selling 500,000 units of Pacira BioSciences Inc stock on 11 March 2013 worth over $13,930,000. On average, Vaughn trades about 320,513 units every 159 days since 2011. As of 11 March 2013 Vaughn still owns at least 2,790,479 units of Pacira BioSciences Inc stock.
You can see the complete history of Vaughn Kai stock trades at the bottom of the page.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon et Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: